A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis (ISR) undergoing repeated percutaneous coronary intervention (PCI). These ...

TAMPA, Fla., Jan. 20, 2025 /PRNewswire/ -- Concept Medical Inc. (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the successful completion ...

WASHINGTON, DC—A sirolimus drug-coated balloon (DCB) is noninferior to paclitaxel-coated DCBs for the treatment of femoropopliteal artery disease, according to data from the SIRONA trial, the first ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window For ...

Please provide your email address to receive an email when new articles are posted on . Four of six patients who used sirolimus had positive responses and discontinued systemic corticosteroids. Three ...

Newark, May 22, 2024 (GLOBE NEWSWIRE) -- The Brainy Insights estimates that the USD 250 million in 2023 global sirolimus market will reach USD 370.06 million in 2033. Sirolimus is also known as ...

NICE is unable to make a recommendation on sirolimus (Hyftor) for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over. This is because Plusultra pharma did not ...

During a recent Polygon meeting, I realized something: I have no idea how to pronounce Balatro, the name of developer LocalThunk’s incredible roguelite poker game that’s occupied every one of my ...

Surmodics Inc. reported positive two-year data from the SWING trial, the first-in-human study to look at the safety of its Sundance Sirolimus drug-coated balloon (DCB) when used to treat occlusive ...

SAN FRANCISCO, CA—In patients with in-stent restenosis after drug-eluting stent implantation, a sirolimus-coated balloon (SeQuent SCB) provides noninferior angiographic results at 9 months compared ...

Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...